ScienceDaily (June 14, 2012) ? Loyola researchers are taking advantage of a quirk in the evolution of fruit fly genes to help develop new weapons against cancer.
A newly discovered fruit fly gene is a simplified counterpart of two complex human genes that play important roles in the development of cancer and some birth defects. As this fruit fly gene evolved, it split in two. This split has made it easier to study, and the resulting insights could prove useful in developing new cancer drugs.
"Evolution has given us a gift," said Andrew K. Dingwall, PhD, senior author of a paper that describes how his team identified and analyzed the split gene. Their findings are published in the June issue of the? journal Development.
When normal cells develop, they differentiate into particular types, such as bone cells or muscle cells, and reproduce in an orderly manner. The process is governed by genes and hormones that work in concert. Two of these genes are known as MLL2 and MLL3. Cancer cells, by contrast, undergo uncontrolled division and reproduction.
Since 2010, a growing number of cancers have been linked to mutations in the MLL2 and MLL3 genes. These cancers include non-Hodgkin's lymphoma, colorectal cancer, kidney cancer, bladder cancer and a brain tumor called medulloblastoma. There also is evidence that MLL2 and MLL3 mutations are involved in breast and prostate cancers.
The MLL2 and MLL3 genes are similar to one another. Each has more than 15,000 building blocks called base pairs -- more than 10 times the number found in a typical gene. Because these genes are so large and complex, they are difficult to study.
In the fruit fly, the counterpart gene to MLL2 and MLL3 split into two genes named TRR and CMI. Each carried information critical for normal gene regulation, and they wound up on different chromosomes. The parsing of the MLL2/MLL3 genetic information into smaller genes in the fruit fly made study of the gene functions much easier; it allowed the researchers unprecedented opportunities to explore the role the human genes play in the development of cancers.
"This fruit fly gene gives us unique insight into the massive human MLL2 and MLL3 genes that are almost impossible to study because they are so large," Dingwall said.
Dingwall's team studied the function of the fruit fly gene by inducing various mutations and then observing the effects on the flies. This will lead to better understanding of what goes wrong when mutations in MLL2 and MLL3 genes trigger the uncontrolled reproduction of cancer cells in humans. This in turn could help researchers develop drugs that would redirect cancer cells to differentiate into normal cells, Dingwall said.
The study was funded through a grant from the National Science Foundation, with additional support from the National Institutes of Health.
Dr. Dingwall is an associate professor in the Oncology Institute and Department of Pathology at Loyola University Chicago Stritch School of Medicine. Co-authors are Claudia Zraly, PhD (joint first author and senior co-author); Chhavi Chauhan (joint first author); Megan Parilla; and Manuel Diaz, MD.
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Loyola University Health System.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
- C. Chauhan, C. B. Zraly, M. Parilla, M. O. Diaz, A. K. Dingwall. Histone recognition and nuclear receptor co-activator functions of Drosophila Cara Mitad, a homolog of the N-terminal portion of mammalian MLL2 and MLL3. Development, 2012; 139 (11): 1997 DOI: 10.1242/dev.076687
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
ruben studdard black friday sales 2011 black friday sales 2011 whitney duncan bradley cooper roger craig roger craig
No comments:
Post a Comment